One coordinated E. coli-based gene-to-GMP biomanufacturing pathway from strain design to clinical supply:
Integrated microbial biologics development between enGenes and NorthX Biologics delivers a faster E. coli-based gene-to-GMP biomanufacturing pathway that gives decision-grade data in weeks, cutting 3 – 6 months in the GMP biomanufacturing timeline
Most E. coli programs don’t stall in the lab. They stall at handover, when one team’s expression system must be reworked for another.
The NorthX – enGenes “gene-to-GMP” pathway offers an integrated route from strain development to full GMP manufacturing for E. coli-based biologics built on enGenes’ proprietary growth-decoupled eXpress™ expression platform. We engineer the expression system for manufacturability and validate it under fed-batch conditions before process development begins. This typically removes 3-6 months of tech transfer and re-development and gives you decision-grade data within weeks. You can use the system at NorthX at no extra cost through a perpetual, royalty-free right of use, with portability if you later choose to manufacture elsewhere.
Reliable data early | No surprises at scale-up.
Where microbial development goes wrong and how we fixed it
The real pressure
Why manufacturing success is decided earlier than you think
Biopharma teams are being asked to do more with less.
- Less capital.
- Faster timelines.
- Higher investor expectations.
- Rising pressure on manufacturing economics.
In that environment, early microbial development isn’t slow because of a lack of innovation – it’s slow because of fragmentation.
Most E. coli programs don’t stall in the lab. They stall at handover, when one team’s expression system must be reworked for another.
Where it breaks down
The development-to-manufacturing gap costs you months – and you pay for it late.
- Expression systems are selected without manufacturing in mind, so process development starts from an unoptimised construct.
- Critical data is lost at every handover: CRO → CDMO → internal teams – and gets reinterpreted or re-run.
- Early-stage teams reach process development without decision-grade data to support Go/No-Go calls or investor conversations.
The result: the handover alone typically adds 3 – 6 months and pushes risk into the most expensive, latest stage of the program.
The joint solution
We remove the handover by running expression-system development, process development, and GMP manufacturing as one coordinated programme, not a new step, but a new way to structure the whole process.
One integrated E. coli-based GMP manufacturing pathway, engineered for manufacturability from day one, cuts months from the pathway by eliminating handoff delays.
What our integrated E. coli-based gene-to-GMP biomanufacturing pathway does that traditional CRO-to-CDMO models don’t.
Traditional approach
- Multiple vendors & contracts
- Data lost between steps
- Re-development for scale-up
- Late-stage surprises
Integrated pathway
- One coordinated programme
- Continuous data flow
- Built for scale-up from day one
- Early-stage validation
What you gain
Faster path to clinic
Fewer handovers between strain development and manufacturing means fewer months added back onto your timeline.
Lower scale-up risk
Your process is validated under fed-batch conditions before scale-up begins, not discovered for the first time once you’re there.
Earlier Go/No-Go decisions
Decision-grade data arrives in weeks instead of months, so program calls get made on real numbers, not projections.
Why months saved matter for runway and valuation
For a venture-backed program, getting to clinic sooner means more runway and an earlier case to make at the next raise. Saving 3-6 months isn’t just a scheduling win – it changes the financing conversation.
| Outcome | Conventional (CRO → CDMO) | Integrated pathway |
| Time to decision-grade data | Months | Weeks |
| Handover penalty | +3-6 months of tech transfer / re-development | Eliminated |
| Rework in process development | Common (unoptimised construct) | Reduced – pre-validated under fed-batch |
| Soluble titers | Platform-dependent | >10 g/L (eXpress™) |
| Project governance | Multiple vendors & contracts | 1 programme, 1 team, 1 timeline |
How does the integrated gene-to-GMP biomanufacturing pathway work:
Stage 1 – Gene concept and target definition
Led by: client brief
Output: The target protein is defined, giving both teams a clear starting brief to design against.Stage 2 – Strain & vector design
Led by: enGenes
Output: A host and vector system is engineered specifically for that target protein.Stage 3 – Expression screening
Led by: enGenes
Output: Up to eight candidate constructs are ranked at microscale, narrowing the field to the strongest performers.Stage 4 – Fed-batch feasibility
Led by: enGenes
Output: The leading construct is confirmed under fed-batch conditions at 1 L scale, and packaged into a tech-transfer file for handover.Stage 5 – Process development
Led by: NorthX
Output: Upstream, midstream, and downstream process work is carried out on the same optimised system, with nothing re-screened or re-selected.Stage 6 – Scale-up & analytics
Led by: NorthX
Output: The process is scaled up, with analytical methods validated and pilot runs confirming performance at larger scale.Stage 7 – GMP manufacturing
Led by: NorthX
Output: A clinical or commercial batch is produced under GMP, with full documentation delivered alongside it.
Indicative timeline from strain design to GMP biomanufacturing
Why does this partnership work?
| enGenes Biotech (Vienna, since 2014) |
|---|
| – eXpress™ growth-decoupled production – eXtra™ secretion – eXpand™ ncAA – eXchange™ marker-free – High-throughput strain & vector screening – Fed-batch feasibility 30+ peer-reviewed publications · 9 patents & applications |
| NorthX Biologics (Sweden, GMP since 1992) |
|---|
| – Process development (USP/MSP/DSP) – Analytical method development – Scale-up to pilot & GMP – Full regulatory infrastructure 30+ years of GMP heritage Sweden’s national innovation hub (2021) |
Get insights about how this partnership works from our Technical Team
Fixed-scope packages for microbial strain development
Clear scope | Clear pricing | No lock-in.
1
Fixed-scope packages with defined deliverables (feasibility report, research cell banks, tech-transfer package.
2
Use your expression system at NorthX at no extra cost – a perpetual, royalty-free right to use the developed system within NorthX manufacturing, included in the service fee.
3
Full portability available if you ever choose to manufacture elsewhere
Proven results in E. coli expression system development
Our expertise is backed by real validated data drawn from actual runs on the eXpress™ platform and GMP batches at NorthX, not projected estimates.
Decision-grade expression data in weeks, not months
>10 g/L soluble titers on the eXpress™ platform
Demonstrated reduction in rework during process development.
30+ years of clinical & commercial GMP track record at NorthX Biologics
Engagement options:
Expression
packageFor whom
Early programs needing
a fast read_____________________
What you get
Rapid feasibility & expression assessment
Development package
For whom
Programs preparing
to scale_____________________
What you get
Expression + process readiness
Earlier go/no-go decisions
For whom
Teams wanting one partner
end-to-end_____________________
What you getFully integrated pathway to GMP
Frequently asked questions
It’s an integrated pathway for microbial (E. coli) biologics, combining enGenes’ expression-system engineering with NorthX’s GMP process development and manufacturing — run as one programme instead of separate CRO and CDMO engagements. ontent
By eliminating the CRO-to-CDMO handover, it typically removes 3–6 months of tech transfer and re-development and delivers decision-grade feasibility data in weeks
Soluble titers above 10 g/L for suitable targets, using enGenes’ growth-decoupled E. coli expression platform.
Recombinant proteins, peptides, plasmid DNA, and bioconjugates produced in E. coli.
Early- and clinical-stage biopharma teams that need decision-grade data fast, want to de-risk scale-up, and prefer a single accountable partner from strain to GMP.
Yes — clients receive a perpetual, royalty-free right to use the developed system within NorthX manufacturing at no additional cost, with portability available if they later manufacture elsewhere.
The expression system is engineered for manufacturability from the start and validated under fed-batch before process development begins, so there’s no data loss, no reinterpretation, and no re-development at the handover.
